To ascertain whether miR-4458 could regulate AML cells function by targeting DOCK1, we first performed CCK assay to evaluate the viability of U937 and HL60 cells transfected with DOCK1 siRNA (si-DOCK1 group) and miR-4458 inhibitor (inhibitor group) or co-transfected with DOCK1 siRNA and miR-4458 inhibitor (inhibitor + si-DOCK group). The gene discussed is DOCK1; the disease is acute myeloid leukemia.